Lori S. Friedman

16.4k citations

106 papers · 7.4k indexed · 2 hit papers · h-index 42

Impact in

Oncology top 1%
- Cancer-related Molecular Pathways
- HER2/EGFR in Cancer Research
Cancer Research top 1%
- Cancer Genomics and Diagnostics

Papers in

Physiology 6
Oncology 29
- HER2/EGFR in Cancer Research 8

Co-authors: Mary‐Claire King Marcia Belvin Deepak Sampath Klaus P. Hoeflich Elizabeth Ostermeyer S E Rowell Csilla I. Szabo Patrick J. Dowd
Journals: Cancer Research (27 papers)Clinical Cancer Research (7 papers)Molecular Cancer Therapeutics (7 papers)Genomics (4 papers)Blood (4 papers)
Partner nations: United States United Kingdom France

In The Last Decade

Lori S. Friedman

98 papers receiving 7.1k citations

Hit Papers

align trajectories log scale

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 2009 · 651 citations

Peers

Countries citing papers authored by Lori S. Friedman

Since Specialization

Citations

This map shows the geographic impact of Lori S. Friedman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lori S. Friedman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lori S. Friedman more than expected).

Fields of papers citing papers by Lori S. Friedman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lori S. Friedman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lori S. Friedman. The network helps show where Lori S. Friedman may publish in the future.

Co-authors

The 25 scholars most cited alongside Lori S. Friedman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lori S. Friedman Line = papers co-authored together Lori S. Friedman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer Cancer Research Communications ·M. Dorso, Payal T. Patel, Aleksandr Pankov, Jacob A. Boyer, Rajesh K. Soni, Isabella Del Priore, Omar Hayatt, Amanda Kulick, Connor J. Hagen, Elisa de Stanchina, Melissa R. Junttila, Anneleen Daemen, Lori S. Friedman, Ronald C. Hendrickson, Sarat Chandarlapaty	2023	2
2	The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer Breast Cancer Research and Treatment ·Aditya Bardia, Ingrid A. Mayer, Eric P. Winer, Hannah M. Linden, X. Cynthia, Barbara A. Parker, Meritxell Bellet, Carlos L. Arteaga, Sravanthi Cheeti, Mary Gates, Ching‐Wei Chang, Jill Fredrickson, Jill M. Spoerke, Heather M. Moore, Jennifer M. Giltnane, Lori S. Friedman, Edna Chow Maneval, Iris T. Chan, Komal Jhaveri	2022	14
3	Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models Molecular Cancer Therapeutics ·Heather M. Moore, Heidi Savage, Carol O’Brien, Wei Zhou, Ethan S. Sokol, Michael E. Goldberg, Ciara Metcalfe, Lori S. Friedman, Mark R. Lackner, Timothy R. Wilson	2019	8
4	Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation Molecular Cancer Therapeutics ·Joo Ern Ang, Rupinder Pandher, Joo Chew Ang, Yasmin J. Asad, Alan T. Henley, Melanie Valenti, Gary Box, Alexis de Haven Brandon, Richard D. Baird, Lori S. Friedman, Mika K. Derynck, Bart Vanhaesebroeck, Suzanne A. Eccles, Stan B. Kaye, Paul Workman, Johann S. de Bono, Florence I. Raynaud	2016	16
5	Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer Nature ·Khaled Ali, Dalya R. Soond, Roberto Piñeiro, Thorsten Hagemann, Wayne Pearce, Ee Lyn Lim, Hicham Bouabe, Cheryl L. Scudamore, Timothy C. Hancox, Heather Maecker, Lori S. Friedman, Martin Turner, Klaus Okkenhaug, Bart Vanhaesebroeck	2014	397
6	Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis The Journal of Experimental Medicine ·Adriana Soler, Helena Serra, Wayne Pearce, Ana Angulo‐Urarte, Julie Guillermet‐Guibert, Lori S. Friedman, Francesc Viñals, Holger Gerhardt, Oriol Casanovas, Mariona Graupera, Bart Vanhaesebroeck	2013	56
7	The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma Oncogene ·Veerendra Munugalavadla, Sanjeev Mariathasan, Dionysos Slaga, Cheng Du, Leanne Berry, Geoff Del Rosario, Y. Yan, Marigold Boe, Ling Sun, Lori S. Friedman, Marta Chesi, P. Leif Bergsagel, Allen Ebens	2013	37
8	A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal Clinical Cancer Research ·Giuseppe Floris, Agnieszka Woźniak, Raf Sciot, Haifu Li, Lori S. Friedman, Thomas Van Looy, Jasmien Wellens, Peter Vermaelen, Christophe M. Deroose, Jonathan A. Fletcher, Maria Dêbiec‐Rychter, Patrick Schöffski	2012	59
9	Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models Clinical Cancer Research ·Jill M. Spoerke, Carol O’Brien, Ling Huw, Hartmut Koeppen, Jane Fridlyand, Rainer K. Brachmann, Peter M. Haverty, Ajay Pandita, Sankar Mohan, Deepak Sampath, Lori S. Friedman, Leanne Ross, Garret M. Hampton, Lukas C. Amler, David S. Shames, Mark R. Lackner	2012	149
10	ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors Molecular Cancer Therapeutics ·Georgia Hatzivassiliou, Bonnie Liu, Carol O’Brien, Jill M. Spoerke, Klaus P. Hoeflich, Peter M. Haverty, Robert Soriano, William F. Forrest, Sherry Heldens, Huifen Chen, Karen Toy, Connie Ha, Wei Zhou, Kyung Song, Lori S. Friedman, Lukas C. Amler, Garret M. Hampton, John G. Moffat, Marcia Belvin, Mark R. Lackner	2012	155
11	GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo Clinical Cancer Research ·Jeffrey J. Wallin, Jane Guan, Wei Wei Prior, Leslie B. Lee, Leanne Berry, Lisa D. Belmont, Hartmut Koeppen, Marcia Belvin, Lori S. Friedman, Deepak Sampath	2012	73
12	Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response Clinical Cancer Research ·Harvey Wong, Edna F. Choo, Bruno Alicke, Xiao Ding, Hank La, Erin McNamara, Frank‐Peter Theil, Jay Tibbitts, Lori S. Friedman, Cornelis E. C. A. Hop, Stephen E. Gould	2012	96
13	Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition Cancer Research ·Klaus P. Hoeflich, Mark Merchant, Christine Orr, Jocelyn Chan, Doug Den Otter, Leanne Berry, Ian Kasman, Hartmut Koeppen, Ken Rice, Nai-Ying Yang, Stefan Engst, Stuart H. Johnston, Lori S. Friedman, Marcia Belvin	2011	200
14	Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors Cancer Research ·Kyle A. Edgar, Jeffrey J. Wallin, Megan Berry, Leslie B. Lee, Wei Wei Prior, Deepak Sampath, Lori S. Friedman, Marcia Belvin	2010	94
15	Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression Cancer Research ·Klaus P. Hoeflich, Sylvia Herter, Janet Tien, Leo Lap-Yan Wong, Leanne Berry, Jocelyn Chan, Carol O’Brien, Zora Modrušan, Somasekar Seshagiri, Mark R. Lackner, Howard M. Stern, Edna F. Choo, Lesley Murray, Lori S. Friedman, Marcia Belvin	2009	144
16	In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models Clinical Cancer Research ·Klaus P. Hoeflich, Carol O’Brien, Zachary Boyd, Guy Cavet, Steve Guerrero, Kenneth Jung, Tom Januario, Heidi Savage, Elizabeth A. Punnoose, Tom Truong, Wei Zhou, Leanne Berry, Lesley Murray, Lukas C. Amler, Marcia Belvin, Lori S. Friedman, Mark R. Lackner	2009	385
17	Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 Cancer Cell ·Teemu T. Junttila, Robert W. Akita, Kathryn L. Parsons, Carter T. Fields, Gail D. Lewis Phillips, Lori S. Friedman, Deepak Sampath, Mark X. Sliwkowski Hit paper breakdown →	2009	651
18	Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab Clinical Cancer Research ·Evelyn Yao, Wei Zhou, Si Tuen Lee-Hoeflich, Tom Truong, Peter M. Haverty, Jeffrey Eastham‐Anderson, Nicholas Lewin‐Koh, Bert Gunter, Marcia Belvin, Lesley Murray, Lori S. Friedman, Mark X. Sliwkowski, Klaus P. Hoeflich	2009	104
19	Mitotic Checkpoint Inactivation Fosters Transformation in Cells Lacking the Breast Cancer Susceptibility Gene, Brca2 Molecular Cell ·Hyun‐Sook Lee, Alison Trainer, Lori S. Friedman, Fiona Thistlethwaite, Martin Evans, Bruce A.J. Ponder, Ashok R. Venkitaraman	1999	191
20	Two independent polymorphisms at the 17β-hydroxysteroid dehydrogenase (EDH17B) gene (17q21) Human Molecular Genetics ·Lori S. Friedman, Eric D. Lynch, Mary‐Claire King	1993	11

About Lori S. Friedman

Lori S. Friedman is a scholar working on Physiology, Oncology, Molecular Biology, Cancer Research and Genetics, having authored 106 papers that have together received 7.4k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (33 papers), BRCA gene mutations in cancer (14 papers), Advanced Breast Cancer Therapies (13 papers), Melanoma and MAPK Pathways (11 papers), Estrogen and related hormone effects (10 papers), HER2/EGFR in Cancer Research (8 papers), DNA Repair Mechanisms (8 papers) and Genomic variations and chromosomal abnormalities (8 papers). The work is most often cited by research in Oncology (2.5k citations), Cancer Research (1.1k citations), Molecular Biology (4.8k citations), Genetics (1.9k citations) and Genetics (521 citations). Lori S. Friedman has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Mary‐Claire King, Marcia Belvin, Deepak Sampath, Klaus P. Hoeflich, Elizabeth Ostermeyer, S E Rowell, Csilla I. Szabo, Patrick J. Dowd, Eric D. Lynch and Mark X. Sliwkowski. Their work appears in journals such as Cancer Research, Clinical Cancer Research, Molecular Cancer Therapeutics, Genomics and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact